Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure

This article was originally published in The Pink Sheet Daily

Executive Summary

Fee rates for biosimilars could be decoupled from new drug user fees in order to provide more predictable revenue stream.


Related Content

Biosimilars At US FDA: Personnel Spending Losing Influence Over Program
Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts